PRESS RELEASE - 03/20/2018

SANDUSKY, Ohio, March 20, 2018 (GLOBE NEWSWIRE) -- (via OTC PR WIRE) --Rising India, Inc.’s (OTC:RSII) -- Rising Biosciences, Inc., a research and development company focusing on oral and topical pharmaceuticals with strict standards set forward by the pharmaceutical compounding industry, is pleased to announce that it has launched near-term initiatives to expedite growth for long-term shareholder value.

Before and After

Ready for Production

Rising BioScience's Cannophen TM

We are thrilled to announce that Rising Biosciences will also be rolling out its RBS0238 CLINICAL PEPTIDE SERUM (our scar serum) in Q2. “We could not be more excited to announce that after a recent meeting with the manufacturer of our clinical strength peptide serum, we are officially entering production phase for the product line and it will be on sale, available for national distribution, in late April/early May,” states Hall. “This means revenues, revenues and more revenues.”

“As well, we have corresponded in regards to the FDA testing procedures on our TSW pain cream and they continue to progress to what we feel will be near-term completion.”

The Company has also recently hired a seasoned chemist who will serve as Chief Chemist in-house at the Company’s Ohio Laboratory. COO Arthur Hall states, “Our Chief Chemist will be traveling to Florida to train with our staff there on overall procedures and protocol. We are thrilled to have secured talent at this level which will greatly expedite research and development on new product ideas as well as staff expertise in all of our locations.”

“As well, we have purchased analytical equipment which will allow us to do developmental testing on-site as opposed to the costly and timely procedure of shipping to an outside laboratory. The equipment is paid for and scheduled to be installed next week.”

The Company also announces updates on expansion and have entered into contracting stages with two California Producer/Processors, one of which also has operations and facilities in Arizona for manufacturing Cannophen™ and TSW pain cream with CBD/THC. A Producer/Processor grows or extracts (THC, CBD, etc.) directly from flower and also processes and manufactures MMJ products. “We anticipate this to effect a near-term multiplier regarding overall operations and potential revenues.”

“The Medical Marijuana revolution has only begun,” states Hall. “The US government recently updated content pages on the National Cancer Institute’s (an official division of the US Department of Health) website to include information about cannabis and cannabinoids.”

The new updates, implemented in January, include information indicating that cannabis and cannabinoids can kill cancer without damaging the body’s normal cells.

The National Cancer Institute states a number of facts about Antitumor activity and pain relief, among others, citing studies in mice and rats which have shown that cannabinoids may inhibit tumor growth by causing cell death, blocking cell growth, and blocking the development of blood vessels needed by tumors to grow. Laboratory and animal studies have shown that cannabinoids may be able to kill cancer cells while protecting normal cells. As well, it goes on to state that A laboratory study of cannabidiol (CBD) in human glioma cells showed that when given along with chemotherapy, CBD may make chemotherapy more effective and increase cancer cell death without harming normal cells. Studies in mouse models of cancer showed that CBD together with delta-9-THC may make chemotherapy such as temozolomide more effective.

“We are on the cusp of something fantastic here and are grateful for continued shareholder participation. We are developing life-changing products and anticipate continued shareholder value alongside assertive R&D initiatives, partnerships and acquisitions as well as both B2B and B2C sales strategies for our product lines,” concludes Hall.

Hall is planning trips to Colorado and Michigan in the coming weeks to meet with producers and processors in those markets, among others on the company’s agenda.

“Rising Biosciences Inc. along with PAO Group Inc. helping reduce the grip of opiods on America through the responsible use of cannabis”

$RSII on Twitter for LIVE company updates!

Forward-Looking Statements: Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward- looking statements to reflect events or circumstances after the date of this release.


For Investor Inquiries:


Photos accompanying this announcement are available at

Recent Posts